DexCom, Inc. (DXCM)

Market Cap	29.14B
Revenue (ttm)	4.30B
Net Income (ttm)	571.50M
Shares Out	392.16M
EPS (ttm)	1.43
PE Ratio	51.95
Forward PE	31.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,459,936
Open	74.17
Previous Close	75.34
Day's Range	73.47 - 75.11
52-Week Range	57.52 - 93.25
Beta	1.44
Analysts	Strong Buy
Price Target	99.90 (+34.46%)
Earnings Date	Oct 23, 2025

About DXCM

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 14, 2005
• Employees: 10,300
• Stock Exchange: NASDAQ
• Ticker Symbol: DXCM
• Website: https://www.dexcom.com/global

Financial Performance

In 2024, DexCom's revenue was $4.03 billion, an increase of 11.34% compared to the previous year's $3.62 billion. Earnings were $576.20 million, an increase of 6.41%.

Analyst Summary

According to 20 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price target is $99.9, which is an increase of 34.46% from the latest price.

Price Target

$99.9

(34.46% upside)

Analyst Consensus: Strong Buy